Literature DB >> 28785836

Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.

Margaret I Liang1,2, Deanna H Wong1, Christine S Walsh2, Robin Farias-Eisner1, Joshua G Cohen3.   

Abstract

Multi-gene panel testing has expanded the genetic information available to cancer patients. The objective was to assess provider behaviors and attitudes and patient knowledge and attitudes towards genetic counseling and testing. An online survey was distributed to Society of Gynecologic Oncology members and a written questionnaire was administered to patients diagnosed with epithelial ovarian cancer at a tertiary care referral center. Most of the 233 (18% response rate) provider respondents were gynecologic oncologists. Access to a genetic counselor was reported by 87% of providers and 55% deferred all testing to genetic counselors. Of 53 ovarian cancer patient respondents, two-thirds had previously seen a genetic counselor or undergone testing. Patients' attitudes about genetic counseling and/or testing were favorable with respect to themselves (70-81%) and their family members (94%). Less than 25% of patients indicated worrying about health care discrimination, lack of privacy, or high cost. Seventy-seven percent of patients demonstrated a desire to obtain genetic information even if the results were not currently actionable, and 20% of providers stated they test for only those genes with guideline-supported actionable results. Provider practice differences were identified in screening and prevention strategies for patients with deleterious non-BRCA mutations and variants of uncertain significance. The variation in clinical interpretation of results associated with poorly defined cancer risks signals a need for more comprehensive training and guidelines to ensure access to evidence-based care.

Entities:  

Keywords:  Genetic counseling; Genetic testing; Moderate penetrance gene; Ovarian cancer; Panel testing; Variant of uncertain significance

Mesh:

Year:  2017        PMID: 28785836     DOI: 10.1007/s10897-017-0135-2

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  37 in total

1.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Authors:  Amy Finch; Mario Beiner; Jan Lubinski; Henry T Lynch; Pal Moller; Barry Rosen; Joan Murphy; Parviz Ghadirian; Eitan Friedman; William D Foulkes; Charmaine Kim-Sing; Teresa Wagner; Nadine Tung; Fergus Couch; Dominique Stoppa-Lyonnet; Peter Ainsworth; Mary Daly; Babara Pasini; Ruth Gershoni-Baruch; Charis Eng; Olufunmilayo I Olopade; Jane McLennan; Beth Karlan; Jeffrey Weitzel; Ping Sun; Steven A Narod
Journal:  JAMA       Date:  2006-07-12       Impact factor: 56.272

2.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

3.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

4.  American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.

Authors:  Mark E Robson; Angela R Bradbury; Banu Arun; Susan M Domchek; James M Ford; Heather L Hampel; Stephen M Lipkin; Sapna Syngal; Dana S Wollins; Noralane M Lindor
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

5.  Germline RAD51C mutations confer susceptibility to ovarian cancer.

Authors:  Chey Loveday; Clare Turnbull; Elise Ruark; Rosa Maria Munoz Xicola; Emma Ramsay; Deborah Hughes; Margaret Warren-Perry; Katie Snape; Diana Eccles; D Gareth Evans; Martin Gore; Anthony Renwick; Sheila Seal; Antonis C Antoniou; Nazneen Rahman
Journal:  Nat Genet       Date:  2012-04-26       Impact factor: 38.330

6.  Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.

Authors:  Grace Wang; Mary S Beattie; Ninez A Ponce; Kathryn A Phillips
Journal:  Genet Med       Date:  2011-12       Impact factor: 8.822

7.  Genetic counselors and the future of clinical genomics.

Authors:  Barbara Bernhardt
Journal:  Genome Med       Date:  2014-07-02       Impact factor: 11.117

8.  The current state of cancer genetic counseling access and availability.

Authors:  Sara Knapke; Joy Larsen Haidle; Rebecca Nagy; Sara Pirzadeh-Miller
Journal:  Genet Med       Date:  2015-08-06       Impact factor: 8.822

9.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2014-05-31       Impact factor: 41.316

10.  Surveillance of women at high risk for hereditary ovarian cancer is inefficient.

Authors:  A L Oei; L F Massuger; J Bulten; M J Ligtenberg; N Hoogerbrugge; J A de Hullu
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  8 in total

1.  Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center.

Authors:  Adrianne R Mallen; Claire C Conley; Mary K Townsend; Ali Wells; Bernadette M Boac; Sarah Todd; Anjalika Gandhi; Michelle Kuznicki; Bianca M Augusto; McKenzie McIntyre; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil
Journal:  Clin Genet       Date:  2019-11-24       Impact factor: 4.438

2.  Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.

Authors:  Rachel A Pozzar; Fangxin Hong; Niya Xiong; Jill E Stopfer; Manan M Nayak; Meghan Underhill-Blazey
Journal:  Fam Cancer       Date:  2021-03-10       Impact factor: 2.375

3.  Preferences of women with epithelial ovarian cancer for aspects of genetic testing.

Authors:  Brittany A Davidson; Jessie Ehrisman; Shelby D Reed; Jui-Chen Yang; Adam Buchanan; Laura J Havrilesky
Journal:  Gynecol Oncol Res Pract       Date:  2019-01-22

4.  The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.

Authors:  Wonkyo Shin; Gowoon Jeong; Yedong Son; Sang-Soo Seo; Sokbom Kang; Sang-Yoon Park; Myong Cheol Lim
Journal:  Int J Environ Res Public Health       Date:  2021-02-26       Impact factor: 3.390

5.  Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study.

Authors:  Yan Zhang; Siqi Yi; Ciaran B Trace; Marian Yvette Williams-Brown
Journal:  JMIR Cancer       Date:  2022-02-08

6.  Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?

Authors:  Jeanna M McCuaig; Sarah E Ferguson; Danielle Vicus; Karen Ott; Tracy L Stockley; Raymond H Kim; Kelly A Metcalfe
Journal:  Hered Cancer Clin Pract       Date:  2022-04-13       Impact factor: 2.857

7.  "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.

Authors:  Adrianne R Mallen; Claire C Conley; Lindsay Fuzzell; Dana Ketcher; Bianca M Augusto; McKenzie McIntyre; Laura V Barton; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil
Journal:  Support Care Cancer       Date:  2020-09-25       Impact factor: 3.603

Review 8.  Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital.

Authors:  Nicolò Bizzarri; Camilla Nero; Francesca Sillano; Francesca Ciccarone; Marika D'Oria; Alfredo Cesario; Simona Maria Fragomeni; Antonia Carla Testa; Francesco Fanfani; Gabriella Ferrandina; Domenica Lorusso; Anna Fagotti; Giovanni Scambia
Journal:  J Pers Med       Date:  2021-12-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.